Evommune, Inc. Operating Expenses
Evommune, Inc. (EVMN) reported Operating Expenses of $34.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Evommune, Inc. operating expenses for the quarter ending 2026-06-30 was $34.90M, a 51.76% increase year-over-year.
- Evommune, Inc. operating expenses for the quarter ending 2026-03-31 was $23.95M, a 32.84% increase year-over-year.
- Evommune, Inc. operating expenses for the quarter ending 2025-12-31 was $29.72M, a 38.51% increase year-over-year.
- Evommune, Inc. operating expenses for the quarter ending 2025-09-30 was $23.33M, a 41.24% increase year-over-year.
- Evommune, Inc. operating expenses for fiscal 2025 was $94.07M, a 22.15% increase from fiscal 2024.
- Evommune, Inc. operating expenses for fiscal 2024 was $77.01M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.90M 10-Q · filed 2026-08-06 | $58.85M 10-Q · filed 2026-08-06 | $88.56M derived: sum of 3 quarters · filed 2026-08-06 | $111.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $23.95M 10-Q · filed 2026-05-07 | $53.67M derived: sum of 2 quarters · filed 2026-05-07 | $77.00M derived: sum of 3 quarters · filed 2026-05-07 | $99.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $29.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $53.04M derived: sum of 2 quarters · filed 2026-03-05 | $76.04M derived: sum of 3 quarters · filed 2026-08-06 | $94.07M 10-K · filed 2026-03-05 |
| 2025-09-30 | $23.33M 10-Q · filed 2025-12-11 | $46.32M derived: sum of 2 quarters · filed 2026-08-06 | $64.36M 10-Q · filed 2025-12-11 | $85.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $22.99M 10-Q · filed 2026-08-06 | $41.03M 10-Q · filed 2026-08-06 | $62.48M derived: sum of 3 quarters · filed 2026-08-06 | $79.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $18.03M 10-Q · filed 2026-05-07 | $39.49M derived: sum of 2 quarters · filed 2026-05-07 | $56.00M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $21.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $37.97M derived: sum of 2 quarters · filed 2026-03-05 | $77.01M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $16.52M 10-Q · filed 2025-12-11 | $55.56M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |